Clinical Trials Browser

Phase 3 × INDUSTRY × Chemotherapy-Induced Thrombocytopenia × Clear all

NCT03976882 2025-05-16

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.

Phase 3 Completed

Classical hematology

Chemotherapy-Induced Thrombocytopenia

NCT05864014 2025-04-16

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

Phase 3 Active not recruiting

Classical hematology

Chemotherapy-Induced Thrombocytopenia

NCT05261646 2023-09-28

A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

Phase 3 Withdrawn

Classical hematology

Chemotherapy-Induced Thrombocytopenia